Navigation Links
Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011
Date:5/25/2011

MINNEAPOLIS, May 25, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fourth quarter and full fiscal year ended March 31, 2011.

Global sales grew 35% to $4.0 million in the fiscal fourth quarter ended March 31, 2011, compared with $3.0 million in the fourth fiscal quarter a year ago.  The growth reflected strength in U.S. sales, up 54% from the fiscal fourth quarter ended March 31, 2010.  U.S. sales growth was driven by a 43% increase in sales of the Urgent PC Neuromodulation System to $1.3 million compared with the same quarter in the prior fiscal year.  The number of customers in the U.S. who purchased Urgent PC increased to 346 in the fiscal fourth quarter, establishing a new quarterly record for active customers.  The growth of Urgent PC sales follows the availability of the Category I CPT® code for posterior tibial nerve stimulation (PTNS) effective January 2011; positive coverage decisions by 10 of the 13 regional Medicare carriers and a number of private payers; and favorable reimbursement rates.  In addition, with continued focused sales and marketing efforts, sales of Macroplastique in the U.S. increased 60% in the fiscal fourth quarter ended March 31, 2011, compared with the fiscal fourth quarter a year ago.

"The fiscal fourth quarter ended March 31, 2011 was a strong finish to our 2011 fiscal year and demonstrates the growth potential for Uroplasty as adoption of Urgent PC in the U.S. continues to grow," said David Kaysen, President and CEO of Uroplasty, Inc.  "Active customers increased to 346 in the recent quarter from 236 in the fiscal third quarter, reflecting the demand for Urgent PC in the U.S.  We expect the number of active customers will continue to grow."

"We recently announced that effective May 22, NHIC, the regional Medicare carrier for Maine, Massachusetts, New Hampshire, Rhode Island and Vermont, will begin to cover PTNS treatments, and, effective May 1, CIGNA Government Services, which also has a positive coverage policy for PTNS treatments, will become the new Medicare carrier for Kentucky," Mr. Kaysen continued.  "With these additions, 10 of the 13 regional Medicare carriers representing approximately 31 million Medicare lives in 35 states provide coverage for PTNS treatments.  United Healthcare, a nationwide private insurer, and Excellus BlueCross BlueShield, a regional insurer in upstate New York, also recently initiated coverage of PTNS treatments.  We estimate that private payers providing insurance to 70 million lives have elected to provide coverage for PTNS treatments."  

"In addition to demonstrating the benefits of Urgent PC to new physicians, our sales and marketing team is focused on increasing penetration at existing accounts," Mr. Kaysen said.  "At the end of March, we had 31 employed sales representatives, supported in the field by four reimbursement managers.  We expect to expand geographic coverage during fiscal 2012 and have already added four additional representatives since March 31.  In addition to our success with Urgent PC, sales of Macroplastique in the U.S. were also very strong in the quarter.  We anticipate that this strength will continue in the short term because of expected discontinuation of a competing product."

"Fiscal 2011 was a very productive year for the Company.  Supported by sound clinical studies, a well-trained and motivated sales and support staff, and sufficient capital, we are well-positioned to pursue our growth opportunities in the U.S.  We are also moving forward with our plan to explore the regulatory path in the U.S. for Urgent PC to treat fecal incontinence," Mr. Kaysen concluded.

Fiscal Fourth Quarter and Full Year Results for the Period Ended March 31, 2011 Net sales for the fiscal fourth quarter ended March 31, 2011 totaled $4.0 million, an increase of 35% over net sales of $3.0 million for the year-ago quarter.  Fiscal year 2011 net sales were $13.8 million, a 16% increase over fiscal 2010 sales of $11.9 million.  Excluding the impact of foreign exchange translation, sales grew by 19%.

Sales to customers in the U.S. for the fiscal fourth quarter ended March 31, 2011 were $2.4 million, a 54% increase, compared to $1.6 million in the year-ago quarter, and an increase of 21% over fiscal third quarter sales of $2.0 million.  In fiscal 2011, sales to customers in the U.S. totaled $7.9 million, representing a 31% increase over sales of $6.1 million in fiscal 2010.  

Sales in the U.S. of the Urgent PC product for the fiscal fourth quarter ended March 31, 2011 increased 43% to $1.3 million compared with $909,000 for the same period last year and an increase of  26% over fiscal third quarter sales of $1 million.  The Company sold 1,668 Urgent PC lead set boxes to 346 customers in the fiscal fourth quarter ended March 31, 2011 compared to 1,379 boxes to 236 customers in the third fiscal quarter ended December 31, 2010.  The increase in sequential sales of lead set boxes and number of customers in the fourth fiscal quarter is attributable primarily to the listed CPT code assigned effective January 2011 and expanded third-party coverage for PTNS treatments.  For fiscal 2011, Urgent PC sales totaled $4.3 million, representing an increase of 11%, over sales of $3.8 million in fiscal 2010.  

Sales in the U.S. of Macroplastique increased 60% to $1.0 million for the fiscal fourth quarter ended March 31, 2011, from $654,000 for the same period last year.  Fiscal 2011 sales of Macroplastique increased 60% to $3.5 million compared with $2.2 million in fiscal 2010.

Net sales to customers outside of the U.S. for the fiscal fourth quarter ended March 31, 2011 were $1.6 million, an increase of 13% from $1.4 million in the same quarter last year.  Fiscal year 2011 sales totaled $5.9 million, up 1%, compared with $5.8 million in fiscal 2010.  Excluding the impact of foreign exchange translation, sales increased by approximately 7%.

Operating loss for the fiscal fourth quarter ended March 31, 2011 was $1.3 million compared with $561,000 in the prior year quarter.  The fiscal 2011 operating loss was $4.7 million compared with $3.2 million in fiscal 2010.  The operating loss, excluding non-cash charges for share-based compensation and depreciation and amortization expense, of $928,000 in the fiscal fourth quarter increased from approximately $218,000 in the year ago quarter, and increased to $3.1 million in fiscal 2011 from $1.7 million in fiscal 2010.  The increase in loss is largely due to higher expenses related to increased headcount in sales and support staff and higher marketing expense in the U.S.  The net loss for the fiscal fourth quarter ended March 31, 2011 was $1.3 million, or $0.06 per diluted share, compared to a net loss of $577,000, or $0.04 per diluted share, in the year-ago quarter.  Fiscal year 2011 net loss was $4.6 million, or $0.25 per diluted share, versus $3.2 million, or $0.21 per diluted share in fiscal 2010.

Total cash and cash investments at March 31, 2011 were $19.6 million, which includes $14.1 million of cash, cash equivalents and short-term investments and $5.5 million of long-term investments.  In July 2010, the Company raised net proceeds of $14.9 million in a public offering of 4.6 million shares at a price of $3.50 per share.  The Company plans to use the proceeds to expand the U.S. sales and marketing organizations to support the Urgent PC business, and for clinical studies, working capital and general corporate purposes.

Conference Call Uroplasty will host an audio conference call today at 3:30 pm Central, 4:30 pm Eastern, to review the financial results for the fourth quarter and full fiscal year ended March 31, 2011. David Kaysen, President and Chief Executive Officer and Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will host the call. Individuals wishing to participate in the conference call should dial 877-941-6009. An audio replay will be available for 30 days following the call at 800-406-7325 (domestic) or 303-590-3030 (international), with the passcode 4439831#.

About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions.  Our focus is the continued commercialization of our Urgent PC Neuromodulation System, which we believe is the only FDA-cleared minimally invasive, office-based neuromodulation therapy for the treatment of overactive bladder and the associated symptoms of urinary urgency, urinary frequency and urge incontinence.

We also offer Macroplastique Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that we will ever achieve sustained profitability, that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment or that existing carriers and payers will not change their coverage decisions, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.

CPT is a registered trademark of the American Medical Association.For Further Information: Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, and Treasurer

952.426.6140 EVC Group

Doug Sherk/Jenifer Kirtland (Investors)

415.896.6820

Chris Gale (Media)

646.201.5431 UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSThree Months EndedMarch 31,(unaudited)Year EndedMarch 31,2011201020112010Net sales

$4,014,643$2,982,656$13,787,032$11,863,202Cost of goods sold

676,700466,4122,386,4312,058,855Gross profit

3,337,9432,516,24411,400,6019,804,347Operating expensesGeneral and administrative

833,311597,7013,442,1792,798,900Research and development

423,101420,2111,719,5321,785,405Selling and marketing

3,214,6601,848,53410,092,0627,576,776Amortization

211,094211,048843,602845,5534,682,1663,077,49416,097,37513,006,634Operating loss

(1,344,223)(561,250)(4,696,774)(3,202,287)Other income (expense)Interest income

19,66415,63972,42692,736Interest expense

(530)(3,490)(5,067)(14,476)Foreign currency exchange gain (loss)

(2,145)(14,522)10,722(37,552)Other, net

(581)(670)(773)(853)16,408(3,043)77,30839,855Loss before income taxes

(1,327,815)(564,293)(4,619,466)(3,162,432)Income tax expense

57712,34928,83741,379Net loss

$(1,328,392)$(576,642)$(4,648,303)$(3,203,811)Basic and diluted loss per common share

$(0.06)$(0.04)$(0.25)$(0.21)Weighted average common shares outstanding:Basic and diluted

20,584,66814,946,54018,874,00914,944,354UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS

March 31,20112010AssetsCurrent assets:Cash and cash equivalents & short-term investments

$14,084,150$5,811,269Accounts receivable, net

2,085,2621,287,440Inventories

677,960341,497Income tax receivable

-23,820Other

348,100237,321Total current assets

17,195,4727,701,347Property, plant, and equipment, net

1,210,5421,230,771Intangible assets, net

1,725,1362,533,095Long-term investments

5,508,701-Deferred tax assets

87,031108,530Total assets

$25,726,882$11,573,743Liabilities and Shareholders' EquityCurrent liabilities:Accounts payable

$658,107$485,594Current portion – deferred rent

35,00035,000Income tax payable

6,90110,000Accrued liabilities:Compensation

1,597,657903,057Other

247,451212,028Total current liabilities

2,545,1161,645,679Deferred rent – less current portion

77,272112,500Accrued pension liability

475,845601,037Total liabilities

3,098,2332,359,216Total shareholders' equity

22,628,6499,214,527Total liabilities and shareholders' equity

$25,726,882$11,573,743UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Year ended March 31,20112010Cash flows from operating activities:Net loss

$(4,648,303)$(3,203,811)Adjustments to reconcile net loss to net cash used in operations:Depreciation and amortization

1,119,2271,138,077Loss  on disposal of equipment

5,358853Amortization of premium on marketable securities

18,910-Share-based consulting expense

11,261-Share-based compensation expense

422,893414,507Deferred income taxes

26,192(39,741)Deferred rent

(35,228)(35,076)Changes in operating assets and liabilities: Accounts receivable

(752,970)(56,052)Inventories

(328,754)172,723Other current assets and income tax receivable

(85,529)(42,827)Accounts payable

170,326(127,355)Accrued liabilities

705,474(152,700)Accrued pension liability, net

(5,322)39,159Net cash used in operating activities

(3,376,465)(1,892,243)Cash flows from investing activities:Proceeds from maturity of marketable securities

7,261,5685,500,000Purchases of marketable securities

(17,318,915)(4,500,000)Purchases of property, plant and equipment

(229,131)(111,154)Proceeds from sales of equipment

-2,800Payments for intangible assets

(35,643)-Net cash (used in) provided by  investing activities

(10,322,121)891,646Cash flows from financing activities:Net proceeds from public offering of common stock

14,917,059-Net proceeds from exercise of  warrants and options

2,542,207-Net cash provided by financing activities

17,459,266-Effect of exchange rates on cash and cash equivalents

(8,376)35,567Net increase (decrease) in cash and cash equivalents

3,752,304(965,030)Cash and cash equivalents at beginning of year

2,311,2693,276,299Cash and cash equivalents at end of year

$6,063,573$2,311,269Supplemental disclosure of cash flow information:Cash paid during the year for interest

$17$7,697Cash paid during the year for income tax

17,549135,032Non-GAAP Financial Measures:  The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss.  The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP.  We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies.  Therefore, our non-GAAP financial measures may not be comparable to those used by other companies.  We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.

We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes and incentive compensation for senior management because we believe such measures are one important indicator of the strength and the operating performance of our business.  Analysts and investors frequently ask us for this information.  We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss for the fourth quarter of fiscal 2011 and 2010 was approximately $928,000 and $218,000, respectively.  Expense AdjustmentsGAAPShare-based
CompensationDepreciationAmortizationNon-GAAPThree Months Ended March 31, 2011Gross Profit

$3,338,000

$4,000

$9,000$3,351,000% of sales

83%83%Operating ExpensesGeneral & administrative

833,000

(101,000)

(36,000)696,000Research and development

423,000

(6,000)

(3,000)414,000Selling and marketing

3,215,000

(34,000)

(12,000)3,169,000Amortization

211,000$(211,000)

-4,682,000

(141,000)

(51,000)

(211,000)

4,279,000Operating Loss

$(1,344,000)

$145,000

$60,000

$211,000

$(928,000)Three Months Ended March 31, 2010Gross Profit

$2,516,000

$4,000

$15,000$2,535,000% of sales

84%85%Operating ExpensesGeneral & administrative

598,000

(22,000)

(40,000)536,000Research and development

420,000

(8,000)

(3,000)409,000Selling and marketing

1,848,000

(24,000)

(16,000)1,808,000Amortization

211,000$(211,000)

-3,077,000

(54,000)

(59,000)

(211,000)

2,753,000Operating Loss

$(561,000)

$58,000

$74,000

$211,000

$(218,000)Our non-GAAP operating loss for fiscal 2011 and 2010 was approximately $3.1 million and $1.7 million, respectively.  Expense AdjustmentsGAAPShare-based
CompensationDepreciationAmortizationNon-GAAPYear Ended March 31, 2011Gross Profit

$11,401,000

$17,000

$52,000$11,470,000% of sales

83%83%Operating ExpensesGeneral & administrative

3,442,000

(269,000)

(150,000)3,023,000Research and development

1,720,000

(27,000)

(10,000)1,683,000Selling and marketing

10,092,000

(121,000)

(63,000)9,908,000Amortization

844,000$(844,000)

-16,098,000

(417,000)

(223,000)

(844,000)

14,614,000Operating Loss

$(4,697,000)

$434,000

$275,000

$844,000

$(3,144,000)Year Ended March 31, 2010Gross Profit

$9,805,000

$27,000

$58,000$9,890,000% of sales

83%83%Operating ExpensesGeneral & administrative

2,799,000

(191,000)

(155,000)2,453,000Research and development

1,785,000

(49,000)

(13,000)1,723,000Selling and marketing

7,577,000

(147,000)

(66,000)7,364,000Amortization

846,000$(846,000)

-13,007,000

(387,000)

(234,000)

(846,000)

11,540,000Operating Loss

$(3,202,000)

$414,000

$292,000

$846,000

$(1,650,000)
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Uroplasty to Present at the JMP Securities Research Conference
2. Clinical Studies Results of Uroplasty Products Scheduled for Presentation at Three Professional Meetings
3. Uroplasty Announces Expanded Insurance Coverage of Posterior Tibial Nerve Stimulation (PTNS) Delivered Using the Urgent® PC Neuromodulation System
4. Uroplasty to Present at ROTH Capital Partners 23rd Annual OC Growth Stock Conference
5. Uroplasty Reports Financial Results for the Third Quarter FY2011
6. Uroplasty to Issue Third Quarter 2011 Results on January 27, 2011
7. Uroplasty Announces Addition of Robert Kill to its Board of Directors
8. Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys Urgent® PC Neuromodulation System
9. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
10. Uroplasty Reports Financial Results for the Second Quarter FY2011
11. Uroplasty to Issue Second Quarter 2011 Results on October 27, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX ... Nationwide Children,s Hospital signed a membership ... accelerate the development of new cures. ... representing over 57 million patients globally, biopharmaceutical companies ... together to improve protocol design, site selection, patient ...
(Date:12/8/2016)... LAVAL, Quebec , Dec. 8, 2016 /PRNewswire/ ... and TSX: VRX) ("Valeant") today announced positive ... vehicle-controlled clinical study to assess the safety and ... in the treatment of plaque psoriasis. ... adult subjects with moderate to severe psoriasis, IDP-118 ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, LLC ... obtained proof-of-mechanism for neflamapimod (previously code named VX-745), ... 2a clinical trials that demonstrated significant Alzheimer,s disease ... (12-week treatment) and Study 303 (6-week treatment) are ... in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... , ... December 08, 2016 , ... Premier Fitness Camp ... FIT , the ultimate weight loss and wellness program, at their world headquarters of ... to provide immediate and long-term results to anyone seeking weight loss, personal development, a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that it had joined the Pharmaceutical Supply Chain ... organization to unite pharmaceutical and healthcare companies that share a vision of better, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... California Senate Bill ... payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical ... Institute (WCRI) . , According to the study, medical payments per claim in California ...
Breaking Medicine News(10 mins):